5th How to Diagnose and Treat
Multiple Myeloma
April 3-5, 2025 – Vienna, Austria
Chairs: Hermann Einsele (Würzburg), Maria Krauth (Vienna),
Maria-Victoria Mateos (Salamanca), Omar Nadeem (Boston)

Thursday, April 3, 2025

08:30-08:40 Welcome

SESSION I – How I treat smoldering myeloma (SMM)
Chair: Omar Nadeem (Boston)

08:40-08:55	Interactive case: Smoldering myeloma	Hermine Agis (Vienna)
08:55-09:00	*Discussion*	
09:00-09:20	Case-based lecture: High risk smoldering myeloma	Elizabeth O'Donnell (Boston)
09:20-09:25	*Discussion*	
09:25-09:45	Case-based lecture: Drivers of progression of smoldering myeloma	Irene Ghobrial (Boston)
09:45-09:50	*Discussion*	
09:50-10:10	Case-based lecture: Do we need to treat high risk SMM?	Heinz Ludwig (Vienna)
10:10-10:15	*Discussion*	
10:15-10:20	Brief oral communication *Low vaccination rates against seasonal influenza and pneumonia in MGUS and MM patients after COVID-19 pandemics: a real-life survey*	Alessandra Romano (Catania)
10:20-10:23	*Discussion*	
10:23-10:45	*Panel discussion*	

10:45-11:15 Coffee Break

SESSION II – How I treat newly diagnosed multiple myeloma
Chair: Maria Krauth (Vienna)

11:15-11:22	Interactive case: Newly diagnosed transplant eligible multiple myeloma	Charlotte Pawlyn (London)
11:22-11:25	*Discussion*	
11:25-11:45	Case-based lecture: Do we still need transplant in first-line therapy?	Hartmut Goldschmidt (Heidelberg)
11:45-11:50	*Discussion*	

11:50-12:10 Case-based lecture: How to treat the frail patient — Monika Engelhardt (Freiburg)
12:10-12:15 *Discussion*

12:15-12:35 Case-based lecture: — Alessandra Larocca (Turin)
Novel therapeutic approaches for frail multiple myeloma patients
12:35-12:40 *Discussion*

12:40-12:47 Interactive case: — Siobhan Glavey (Dublin)
Newly diagnosed transplant-ineligible patient
12:47-12:50 *Discussion*

12:50-12:55 Brief oral communication — Rosin McAvera (Dublin)
SKY92 molecular profiling in combination with MRD risk profiling to identify high-risk multiple myeloma patients in Ireland (SKIP-MM)
12:55-12:58 Discussion

12:58-13:20 Panel discussion

13:20-14:35 Lunch

SESSION III – From risk stratification to risk-based therapy?
Chair: Hermann Einsele (Würzburg)

14:35-14:42 Interactive case: — Elena Zamagni (Bologna)
How I diagnose the high-risk patient
14:42-14:45 *Discussion*

14:45-15:05 Case-based Lecture: — Martin Kaiser (London)
Should the high-risk patient be treated differently?
15:05-15:10 *Discussion*

15:10-15:30 Case-based lecture: — Roman Hajek (Ostrava)
Should we add immunotherapy in high-risk patients?
15:30-15:35 *Discussion*

15:35-15:50 Case-based lecture: — Marc Raab (Heidelberg)
Precision medicine in multiple myeloma
15:50-15:55 *Discussion*

15:55-16:02 Interactive case: — Martin Kaiser (London)
How I treat a high-risk MM patient in the first line
16:02-16:05 *Discussion*

16:05-16:10 Brief oral communication — Niamh McAuley (Dublin)
A novel approach to treat high-risk multiple myeloma: JAM-A antagonism using novel RGD-Mimetic peptides
16:10-16:13 Discussion

16:13-16:40 Panel discussion

16:40-17:10 Coffee break

17:10-17:50 DEBATE 1 – Should we use MRD testing to determine therapy in multiple myeloma?
Chair: Heinz Ludwig (Vienna)

Audience votes

17:10-17:25	YES	Omar Nadeem (Boston)
17:25-17:40	NO	Klaus Podar (Vienna)
17:40-17:50	*Discussion*	

Audience votes again

17:50-18:30 DEBATE 2 – Is CAR T cell therapy replacing autologous SCT?
Chair: Hermann Einsele (Würzburg)

Audience votes

17:50-18:05	YES	Leo Rasche (Würzburg)
18:05-18:20	NO	Francesca Gay (Turin)
18:20-18:30	*Discussion*	

Audience votes again

18:35-19:45 ***Welcome Get-Together Buffet Dinner***

Friday, April 4, 2025

08:15-09:15 3 Simultaneous Meet the Expert sessions

1.	How to sequence therapy in RRMM	Maria Krauth (Vienna)
2.	Role of MoAb in first-line therapy	Niklas Zojer (Vienna)
3.	How to manage infections in MM patients	Heinz Ludwig (Vienna)

09:25-10:25 **SATELLITE SYMPOSIUM**
New perspective for RRMM TCR Patients – Putting efficacy, safety and quality of life as a combined option
Deepen the knowledge about melflufen with practical patient experience
Chair: Elena Zamagni (Bologna)
Speakers : Marion Högner (Munich), Udo Holtick (Cologne), Javier de la Rubia (Valencia)

This symposium is organised and sponsored by Oncopeptides

10:25-10:55 Coffee Break and Poster viewing

SESSION IV – How I treat relapsed multiple myeloma
Chair: Maria Krauth (Vienna)

10:55-11:02	Interactive case: The revolution in the management of relapsed/refractory Multiple Myeloma	Claudio Cerchione (Bologna)
11:02-11:05	*Discussion*	

11:05-11:25	Case-based lecture: How I treat first relapse	Rakesh Popat (London)
11:25-11:30	*Discussion*	
11:30-11:50	Case-based lecture: How to use T cell engagers in relapse multiple myeloma	Hermann Einsele (Würzburg)
11:50-11:55	*Discussion*	
11:55-12:15	Case-based lecture: Novel agents in relapsed multiple myeloma	Michel Delforge (Leuven)
12:15-12:20	*Discussion*	
12:20-12:27	Interactive case: Optimal sequence at relapse	Niels van de Donk (Amsterdam)
12:27-12:30	*Discussion*	
12:30-12:35	Brief oral communication *Evaluation of attrition rates in real-life setting: a single-center survey in the last 12 years (2012-2024)*	Alessandra Romano (Catania)
12:35-12:38	*Discussion*	
12:38-13:00	*Panel discussion*	

13:00-14:15 Lunch

14:15-14:55 DEBATE 3 – Cell free DNA / circulating tumor cells to replace BM-biopsy and MRD measurement
Chair: Martin Kortüm (Würzburg)

Audience votes

14:15-14:30	YES	Noemi Puig (Salamanca)
14:30-14:45	NO	Paula Tabares (Würzburg)
14:45-14:55	*Discussion*	

Audience votes again

14:55-15:25 Coffee break and Poster Viewing

SESSION V - You can't be immune for immune therapy anymore
Chair: Omar Nadeem (Boston)

15:25-15:32	Interactive case: How to use novel immunotherapies	Klaus Podar (Vienna)
15:32-15:35	*Discussion*	
15:35-15:55	Case-based lecture: CAR-T in multiple myeloma	Adam Sperling (Boston)
15:55-16:00	*Discussion*	
16:00-16:20	Case-based lecture: Novel targets for CAR T cells in multiple myeloma	Sophia Danhof (Würzburg)
16:20-16:25	*Discussion*	
16:25-16:45	Case-based lecture: Bi- and trispecific antibodies	Hermann Einsele (Würzburg)
16:45-16:50	*Discussion*	
16:50-17:10	Case-based lecture:	Paola Neri (Calgary)

How to predict outcome of CAR-T cell and T-cell Engager treated patients

17:10-17:15 *Discussion*

17:15-17:35 Case-based lecture: Nizar Bahlis (Calgary)
Role of antigen loss in CAR T cell engaging antibodies

17:35-17:40 *Discussion*

17:40-17:45 Brief oral communication Izabela Cymer (Dublin)
Systemic dissemination and responsiveness to clinically-used therapeutics is recapitulated in a chick embryo xenograft model of multiple myeloma

17:45-17:48 Discussion

17:48-18:10 Panel discussion

Saturday, April 5, 2025

08:20-09:20 3 Simultaneous Breakfast Meet the Expert Sessions

1. How to use genetics in multiple myeloma — Martin Kortüm (Würzburg)
2. Novel agents (not immunal therapy) — Kenneth C. Anderson (Boston)
3. Novel agents (immunal therapy) — Paola Neri (Calgary)

09:30-09:55 Keynote lecture: the future of multiple myeloma
Chair: Hermann Einsele (Würzburg)

09:30-09:50 Multiple myeloma treatment in 2030 Kenneth C. Anderson (Boston)
09:50-09:55 Discussion

SESSION VI – Other plasma cell dyscrasias
Chair: Steven Treon (Boston)

09:55-10:02 Interactive case: Steven Treon (Boston)
How I treat Waldenstrom's macroglobulinemia

10:02-10:05 *Discussion*

10:05-10:25 Case-based lecture: Mario Nuvolone (Pavia)
How I treat amyloidosis

10:25-10:30 *Discussion*

10:30-10:50 Case-based lecture: Hermine Agis (Vienna)
Is this myeloma kidney? A case of significantly elevated free serum light chains and kidney failure

10:50-10:55 *Discussion*

10:55-11:15 Case-based lecture: Wolfgang Willenbacher (Innsbruck)
Bone disease in multiple myeloma

11:15-11:20 *Discussion*

11:20-11:27 Interactive case Martin Kortüm (Würzburg)
Supportive care in multiple myeloma today

11:27-11-30 *Discussion*

11:30-11:35 Brief oral communication Ciprian Tomuleasa (Cluj Napoca)
Real life experience with siltuximab in multicentric Castleman disease

11:35-11:38 Discussion

11:38-12:00 Panel discussion

12:00-12:10 Closing remarks

MEETING CLOSURE